检测灵敏度	0.33 ng/mL
测定范围	1.6-100 ng/mL
检测样本类型/体积	{Plasma=25 µL, Serum=25 µL, Supernatant=25 µL, Urine=25 µL}
手工操作时间	15 min
总时间	3 hr 10 min
均相（无需洗涤）	No
批间差异	12.9%
批内差异	9.2%
仪器设备	Absorbance Microplate Reader
产品规格	128 tests
产品成分	Pre-coated 96 well Microplate Detection Antibody Anti-IgG-HRP Sample Diluent, lyophilized Standard (8-well strips x 4) Wash Buffer Concentrate Substrate Solution Sample Diluent Stop Solution Lysis Buffer 10x Adhesive Plate Covers
运输条件	Wet ice
储存温度	-20℃
蛋白名称	CD30
物种	Human
检测试剂盒格式	Instant ELISA Kit
检测抗体结合物	HRP
标签或染料	HRP

 

The Human Soluble CD30 ELISA quantitates Hu sCD30 in human serum, plasma, cell culture supernatants, urine, or other body fluids. The assay will exclusively recognize both natural and recombinant Hu sCD30.

 

原理方法

The Human sCD30 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the binding of the second (detector) antibody to the target on a different epitope from the capture antibody. An antibody conjugated with enzyme binds the formed sandwich. After incubation and washing steps to rid the microplate of unbound substances, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen.

 

严格验证

Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

 

靶标信息  

 

CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. CD30 is a positive regulator of apoptosis, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. CD30 is expressed by mononuclear cells in Hodgkin's lymphoma, Reed Sternberg cells and most Anaplastic Large Cell Lymphomas (ALCL). CD30 is also expressed by embryonal carcinomas.